The Efficacy of Solifenacin Added to A-Adrenergic Antagonists in the Treatment of Lower Urinary Tract Symptoms in Males with Benign Prostate Hyperplasia (The Iraqi Experience)

Nibbras I. AL-Hamdani* FICMS
Saad D. Daraji ** FICMS, FABU, FEBU
Ali W. Zeki*** FICMS

Abstract:

Background: The response of overactive bladder (OAB) symptoms seen in men with Lower urinary tract symptoms/Benign prostate hyperplasia (LUTS/BPH) raises the possibility that a combination of α-adrenergic blocker therapy with anticholinergic therapy could both reduce the risk of retention or deteriorating bladder function and also add to the treatment of the remaining obstructive symptoms of LUTS/BPH.


Patients and methods: This is a prospective study of 29 patients with benign prostatic hyperplasia already on alpha-blockers, given solifenacin 5mg once daily. International prostate symptom score (IPSS), patient micturition diaries, quality of life index (QOL), post-void residual urine (PVR) and maximum flow rate (Qmax) and urodynamic findings were recorded before and after three months of therapy. Adverse events were documented.

Results: At baseline, the total IPSS was 15.3+5.7 that decreased to 10.8+5.3 (net change -4.5, P value <0.03). Although the mean IPSS for voiding symptoms was not significant, significant change was noted in the storage symptoms (from 8.4+2.4 to 5.1+2.5 P value <0.001). The quality of life index was significantly improved for the patients enrolled from 4.4+1.4 to 2.8+1.3. The maximum flow rate increased from 11.6+5.7 to 14.3+6.1 with a net change of +2.7 ml/sec (P value <0.01) ml/sec. Two patients stopped the medication because of side effects. The side effects included dry mouth (17.24%) followed by constipation (6.90%) then headache and blurred vision (3.45%) for each. No urine retention developed in any patient.

Conclusions: The use of solifenacin in selected cases in the treatment of LUTS in patients with BPH is highly effective addition to alpha-blockers.

Key words: Lower urinary tract symptoms, benign prostate hyperplasia, Anticholinergic medication.

Introduction:

Benign prostatic hyperplasia (BPH) is a pathologic process that contributes to, but is not the sole cause of, lower urinary tract symptoms (LUTS) in aging men. (1). Since α-Adrenergic monotherapy is effective in improving voiding symptoms and to a certain extent over active bladder symptoms, it is recommended as a first-line treatment for men with benign prostate obstruction (BPO) overactive bladder (OAB) symptoms. However, remaining OAB are sometimes experienced, and such symptoms continuously impair quality of life (QOL). (2). Storage symptoms are currently largely encompassed by the term overactive bladder (OAB) syndrome, which is defined as urgency, frequency, nocturia, and urge incontinence, which is believed to be correlated with underlying detrusor overactivity. These symptoms tend to be more bothersome than voiding symptoms, especially if they are associated with incontinence (3). The development, validation, translation with cultural and linguistic validation of the standardized, self-administered seven-item American Urological Association (AUA) Symptom Index (AUASI), also known as the International Prostate Symptom Score [IPSS] has been a pivotal event in the clinical research of Lower urinary tract symptoms and benign prostate hyperplasia (LUTS and BPH) (4). The IPSS is a helpful tool both in the clinical management of men with lower urinary tract symptoms and in research studies regarding the medical and surgical treatment of men with voiding dysfunction(5). Literature review strongly supports the use of antimuscarinic drugs in the treatment of OAB

*Consultant Urologist, Surgical specialties hospital, Medical city complex.
**Assistant professor, College of medicine, University of Baghdad.
***Senior Lecturer, College of medicine, University of Tikrit Email:Saaduro@yahoo.com
symptoms. They are well tolerated, but there is minimal available evidence on the long-term outcome of medical therapy of mixed OAB and Bladder outlet obstruction (BOO) due to benign prostate hyperplasia (BPH). The short-term data suggest that a combination of antimuscarinic and α-adrenergic blocker therapy is safe with minimal risk of retention or acute urinary retention (AUR) in carefully selected men. Men with significant obstruction and large, persistent residual urine volumes should be considered for surgical therapy rather than the addition of antimuscarinic agents(6). According to treatment recommendations proposed by the 6th International Consultation on New Developments in Prostate Cancer and Prostate Diseases (7), α-blocker and anticholinergic combination therapy is recommended as a first line treatment for men with coexisting bladder outlet obstruction (BOO)OAB symptoms. However, when we consider the promising efficacy of α-blockers on OAB symptoms in men with BPO and adverse events as well as increased medical cost of anticholinergic agents, the add-on of anticholinergic agent following α-blocker monotherapy seems to be clinically practical and acceptable(8). Solifenacin is a tertiary amine and well absorbed from the gastrointestinal tract (absolute bioavailability 90%). The mean terminal half-life is 45 to 68 hours (9). It undergoes hepatic metabolism involving the cytochrome P450 enzyme system (CYP3A4). Solifenacin has a modest selectivity for M3 over M2 receptors and a marginal selectivity over M1 receptors (10). Therapeutically effective doses of solifenacin do not increase heart rate or blood pressure. Solifenacin has a well-documented effect in over active bladder/Detrusor over activity (OAB/DO), and the adverse event profile seems acceptable (11).

**Aim of This study:**
To determine the efficacy and tolerability of 5mg solifenacin for the treatment of lower urinary tract symptoms of BPH patients in addition to α-blockers.

**Patients and Methods:**
This is a prospective study conducted in the Urology Department at the Surgical Specialties Hospital of Baghdad Medical City complex for 28 months (from 1st March 2011 to the end of June 2013). Twenty-nine Patients with benign prostatic hypertrophy on α-blocker therapy complaining of lower urinary tract symptoms were enrolled. The inclusion criteria were male patients over 50 years of age, proved to have prostate enlargement documented by abdominal-pelvic ultrasonography or Trans-rectal ultrasound (TRUS) with LUTS despite alpha blocker therapy for four weeks. Exclusion criteria included large post void residual urine over 100 ml, previous prostate surgery, previous treatment with 5 α-reductase therapy, PSA more than 10ng/ml, and lower urinary tract disorders. In addition (Diabetes mellitus, anatomic disorders), Major cardiac insults: (heart failure, ischemic heart disease), neurogenic bladder dysfunction (excluded by history and examination), Tumor of prostate and bladder (excluded by Digital rectal examination, PSA and urine cytology), or infection (urinalysis with culture and sensitivity). The patients who were enrolled in this study took 5 mg of a solifenacin treatment once a day for three months, The dose was taken four weeks after starting alpha blocker therapy (tamsulosine 0.4 mg); International prostatic symptom score (IPSS), patient micturition diaries, quality of life index (QOL), and post-void residual urine (PVR) were recorded by the interviewer before the addition of solifenacin therapy and after three months of therapy. Urodynamic study was done before starting the medication to confirm the presence of overactive bladder contractions. Overactive bladder is defined as the development of a detrusor contraction exceeding 15 cm H2O at a bladder volume less than 300 ml. Maximum flow rate (Qmax) was measured before starting the medication and after 3 months of therapy. A change in the type and dose of alpha-blocker was not allowed while the study period besides no other drugs was allowed to be added. If the patient experienced adverse events, they were recorded. Statistical analysis was used by SPSS software. A p value of less than 0.05 was considered significant. End point values after three months of therapy was compared to the baseline values by (t test).

**Results:**
Patient Population: Out of 36 patients, 29 patients completed the three months period of the study and submitted to the efficacy analysis because five patients failed to attend for follow up and two patients stopped the medication because of side effects. The mean age of the patients was 61±8 years. The mean PSA for all enrolled patients (29) was 2.8 ng/ml. Of the 29 patients, 13 patients (44.8%) had an overactive bladder. The mean duration of previous failed alpha-blockers was 4.5 months. The alpha-blockers used were: alfuzosin 17 patients and tamsulosin 12 patients. Efficacy Analysis: At baseline, the total IPSS was 15.3±5.7 that decreased to 10.8±5.3 (net change -4.5, P value <0.03). Most of the improvement in the IPSS parameters occurred after 4 weeks of commencing the solifenacin therapy (net change of -3.2). Significant change was noted in the storage symptoms (Table 1). The frequency, urgency and nocturia (3.0±1.2, 3.1±1.3, and 2.8±1.2 respectively) decreased significantly to 2.1±1.0, 1.4±1.3, and 1.6±1.1 respectively (P value <0.001). Effect on Voiding symptoms was not significant. Incomplete emptying (2.2±1.5), weak stream (1.9±1.4), and straining (1.3±1.2) have changed to
The Efficacy of Solifenacin Added to A-Adrenergic Antagonists in The Treatment of Lower Urinary Tract Symptoms in Males with Benign Prostate Hyperplasia (The Iraqi Experience)

Nibbras I. AL-Hamdani

(1.4±1.2, 1.8±1.3, and 1.2±1.1) respectively. A slight rise in intermittency score was noted from (1.6±1.4) to (1.6±1.5). IPSS voiding symptoms change was (-1.0) (P value >0.1). The quality of life index QOL (Table 1) was significantly improved in the patients enrolled from 4.4±1.4 to 2.8±1.3 with a P value of <0.001.

Table (1): changes in the mean of parameters of the IPSS and quality of life index before and after 4 weeks and 12 weeks of solifenacin treatment.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Before Treatment</th>
<th>After 4 Weeks</th>
<th>After 12 weeks</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incomplete emptying</td>
<td>2.2±1.5</td>
<td>1.8±1.3</td>
<td>1.4±1.2</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Frequency</td>
<td>3.0±1.2</td>
<td>2.4±1.2</td>
<td>2.1±1.0</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Intermittency</td>
<td>1.6±1.4</td>
<td>1.6±1.4</td>
<td>1.6±1.5</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Urgency</td>
<td>3.1±1.3</td>
<td>2.5±1.1</td>
<td>1.4±1.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Weak stream</td>
<td>1.9±1.4</td>
<td>1.9±1.2</td>
<td>1.8±1.3</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Straining</td>
<td>1.3±1.2</td>
<td>1.3±1.1</td>
<td>1.1±1.1</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Nocturia</td>
<td>2.8±1.2</td>
<td>2.0±1.3</td>
<td>1.6±1.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IPSS storage symptoms</td>
<td>8.4±2.4</td>
<td>6.2±2.3</td>
<td>5.1±2.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IPSS voiding symptoms</td>
<td>5.9±2.5</td>
<td>5.7±2.5</td>
<td>4.9±2.8</td>
<td>&gt;0.1</td>
</tr>
<tr>
<td>IPSS total score</td>
<td>15.3±5.7</td>
<td>12.1±5.0</td>
<td>10.8±5.3</td>
<td>&lt;0.03</td>
</tr>
<tr>
<td>QOL index</td>
<td>4.4±1.4</td>
<td>3.3±1.5</td>
<td>2.8±1.3</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Total IPSS improvement for patients confirmed to have overactive bladder and those without bladder over activity was not significant. Total IPSS for patient with overactive bladder changed from 15.5±4.6 to 11.6±6.4 (P value >0.05), while patients without overactive bladder changed from 15.6±5.3 to 11.5±5.8 (P value >0.05). (Figure 1).

Regarding post residual urine (Figure 2), a slight rise in the residual urine was noted (from 25.4±34.3 to 26.6±30.2) which was statistically not significant (P value >0.05). Maximum flow rate Qmax (Figure 3) increased from 11.6±5.7 to 14.3±6.1 with a net change of ± 2.7m (P value <0.01).

Safety Analysis: Of the 31 patients submitted to the safety analysis (29 patients completed the study plus 2 patients stopped the medication for side effects), 9 side effects (Fig4) developed in 6 patients (19.35%). Dry mouth was the most common adverse effect that developed in 5 patients (17.24%) followed by constipation in 2 patients (6.90%). Headache and blurred vision each developed in one patient (3.45%). No urine retention developed in any patient.
The Efficacy of Solifenacin Added to A-Adrenergic Antagonists in The Treatment of Lower Urinary Tract Symptoms in Males with Benign Prostate Hyperplasia(The Iraqi Experience)

Discussion:
Benign prostatic hyperplasia (BPH) is a pathologic process that contributes to, but is not the sole cause of lower urinary tract symptoms (LUTS) in aging men (1). LUTS had adverse effects on health related quality of life, including interference with daily activities and decreased psychological well-being, which worsen with symptom severity. LUTS include overactive bladder (OAB) symptoms, e.g. frequency, urgency, and incontinence, and voiding (or obstructive) symptoms, e.g. dribbling, hesitancy, a weak stream, and incomplete emptying (12). Thus, controlling OAB symptoms without aggravating voiding symptoms has become an important therapeutic goal in the management of BPH induced LUTS. α-adrenergic receptor antagonists facilitate urine release in conditions of functionally increased urethral resistance, such as benign prostatic hyperplasia. (13). Even if it is well known that α1-AR antagonists can ameliorate lower urinary tract symptoms (LUTS) in men with benign prostatic enlargement there are no controlled clinical trials showing that they are an effective alternative in the treatment of OAB in this patient category (14,15). Persisting storage symptoms not responding to α1-blockers are frequently observed in a clinical setting. In the subjects evaluated in our study, despite of administration of α-blocker, the IPSS, and QOL index were 15.3 and 4.4, respectively. The IPSS voiding symptoms seemed to be well controlled by α-blocker monotherapy. On the other hand, the IPSS storage symptom score remained high. Thus, additional treatment is mandatory for BPO/LUTS patients with persisting OAB symptoms to improve their QOL. Remaining OAB symptoms are mainly caused by detrusor over activity rather than BPO. (16). There are several mechanisms to explain the highly frequent association of bladder over activity with BPH/LUTS such as denervation hypersensitivity, modulated detrusor properties, increased release of urothelial neurotransmitters, and increased afferent stimulation from the urethra (17). Since anticholinergic agents contribute to improving OAB symptoms through the blockade of muscarinic receptors on the smooth muscle, urothelium, and afferent nerves, they may be effective to control remaining OAB symptoms after α1-blockers monotherapy. For patients with OAB, antimuscarinic drugs appear to be a logical choice (18). In the present study, additional administration of solifenacin for patients with BPO/LUTS treated with α-blocker revealed significant improvement of the remaining OAB symptoms without deterioration of voiding symptoms, Qmax, and PVR. The results of this study demonstrate that the solifenacin decreased OAB symptoms with storage and voiding symptoms in men with BPH in whom α-blocker therapy failed to control these symptoms. The prevalence estimates of BOO in men with LUTS have approached 70%. Furthermore, the prevalence of DO in men with BPH/LUTS has been estimated to be between 40% and 70%.(19). The current results demonstrate that solifenacin was effective for male LUTS and suggested that expensive cystometric and urodynamics diagnostic techniques used to confirm DO and BOO may not be necessary to treat LUTS effectively. Combinations therapies using anticholinergics and α-blockers have also demonstrated promise for symptomatic BOO and DO in some male populations. (20, 21). Although the reasons for the failed efficacy of α-blockers in this population are not well established, it is possible that some patients had idiopathic OAB in the absence of BOO. Because α-blockers may not have direct effects on detrusor contractility, the efficacy of oxybutynin treatment in these men may be attributable only to increased detrusor stability. Decreased detrusor contractions may increase bladder volume at voiding, leading to the observed improvements in hesitancy and intermittency. In addition, neither acute urinary retention nor severe adverse events were observed during the study period (22). The incidence of adverse events was low and urinary retention did not occur in any solifenacin treated men. The increases in Qmax observed with solifenacin treatment further support a low risk of urinary retention. These results are consistent with previous findings in men with BPH and BOO that suggest the inhibitory effect of antimuscarinic agents on detrusor muscle contraction is unlikely to aggravate voiding difficulties in men with OAB symptoms and possible BOO. There are several studies that investigated the add-on effects of anticholinergic...
agents after α1-blockers monotherapy. Most of the studies demonstrated similar results that the IPSS, QOL index, the IPSS storage symptoms, and OABSS were improved and the IPSS voiding symptoms remained unchanged by add-on of anticholinergic agents. No worsening of Qmax and PVR was observed except in one report. In addition, no studies reported development of acute urinary retention (23, 24, 25, 26). Kaplan et al. Reported the efficacy and tolerability of solifenacin add-onto men with residual urgency and frequency (mean urinary frequency ≥ 8 times per 24 hours including ≥1 urgency episode per 24 hours in a bladder diary) after 0.4mg/day of tamsulosin for 4 or more weeks. A total of 398 men were randomized to 12 weeks of solifenacin 5mg + tamsulosin or placebo + tamsulosin. Although there were no significant differences in reductions of urinary frequency per 24 hours (−1.05 versus −0.67, P = .135) and the IPSS storage symptom score (−2.80 versus −2.33, P = .074) between the 2 groups, urgency episode per 24 hours was significantly reduced in the group to add-of solifenacin (−2.16 versus −1.10, P < .001). Urinary retention was reported in seven patients (3%) and required catheterization on solifenacin + tamsulosin whereas none was reported on placebo + tamsulosin. Thus, they concluded that solifenacin + tamsulosin was well tolerated although closer supervision may be required for men with severe BOO. (27). The present study has its limitations because of the small number of patients. However, we are not aware of a similar study in Iraq. The quality of life index QOL and other parameters were significantly improved in agreement with international studies. We do recommend the addition of solifenacin to α-blockers in the treatment of LUTS in patients with BPH.

**Author Contribution:**
Nibbras I. AL-Hamdani: Super Vision
Saad D. Daraji: Super Vision, writing, statistics and Discussion
Ali W. Zeki: Data Collection

**References:**
The Efficacy of Solifenacin Added to A-Adrenergic Antagonists in The Treatment of Lower Urinary Tract Symptoms in Males with Benign Prostate Hyperplasia (The Iraqi Experience)

Nibbras I. AL-Hamdani


